Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Annals of Neurology

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9PMID 11079549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brains of Aged Apolipoprotein E‐Deficient Mice Have Increased Levels of F2‐Isoprostanes, In Vivo Markers of Lipid Peroxidation

  1999cited by this paper
• Molecular basis of the neurodegenerative disorders.

  1999cited by this paper
• Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine.

  1999cited by this paper
• F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo.

  1999cited by this paper
• Oxidative Alterations in Alzheimer's Disease

  1999cited by this paper
• Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid*

  1998cited by this paper
• Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

  1998cited by this paper
• Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation.

  1996cited by this paper
• Fisher Symposium: Strategies for the Prevention of Alzheimer Disease—Overview of Research Planning Meeting III

  1996cited by this paper
• Performance of the Dementia Severity Rating Scale: A Caregiver Questionnaire for Rating Severity in Alzheimer Disease

  1996cited by this paper
• Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation (*)

  1996cited by this paper
• Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

  1995cited by this paper
• Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain

  1995cited by this paper
• Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

  1995cited by this paper
• Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease

  1994cited by this paper
• Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery

  1994cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.

  2026cites this paper
• Impairment of Tricarboxylic Acid Cycle (TCA) Cycle in Alzheimer's Disease: Mechanisms, Implications, and Potential Therapies

  2025cites this paper
• Ferroptosis-related stress during aging and its relevance to disease.

  2025cites this paper
• LC-MS/MS based analytical strategies for the detection of lipid peroxidation products in biological matrices.

  2025cites this paper
• Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits

  2025cites this paper
• Roles of the Receptor for Advanced Glycation End Products and Its Ligands in the Pathogenesis of Alzheimer’s Disease

  2025cites this paper
• Aging-associated DNA methylation of LEF1 modulates inflammation and neurodegenerative pathways

  2025cites this paper
• Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics

  2024cites this paper
• Oxidative stress in the brain–lung crosstalk: cellular and molecular perspectives

  2024cites this paper
• Differential impact of eicosapentaenoic acid and docosahexaenoic acid in an animal model of Alzheimer’s disease

  2024cites this paper
• Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

  2024cites this paper
• Local myelin damage in the hippocampus fluctuates gut microbiome profile and memory.

  2023cites this paper
• The Relationship of Preconception and Early Pregnancy Isoprostanes with Fecundability and Pregnancy Loss

  2023cites this paper
• Capturing wild animal welfare: a physiological perspective

  2023cites this paper
• Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease

  2022cites this paper
• Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview

  2022cites this paper
• The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress

  2022cites this paper
• DHA and Its Elaborated Modulation of Antioxidant Defenses of the Brain: Implications in Aging and AD Neurodegeneration

  2021cites this paper
• Cyclopentenone Prostaglandins: Biologically Active Lipid Mediators Targeting Inflammation

  2021cites this paper
• Association of F2-isoprostane levels with Alzheimer's disease in observational studies: a systematic review and meta-analysis.

  2021cites this paper
• Metabolic Profiling and Quantitative Analysis of Cerebrospinal Fluid Using Gas Chromatography–Mass Spectrometry: Current Methods and Future Perspectives

  2021cites this paper
• Hypoxia-Induced Neuroinflammation in Alzheimer’s Disease: Potential Neuroprotective Effects of Centella asiatica

  2021cites this paper
• A Review of Oxidative Stress Products and Related Genes in Early Alzheimer’s Disease

  2021influential citation
• Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation

  2020cites this paper
• Treating Alzheimer’s disease pathology: Present to alternative modalities

  2020cites this paper
• ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease

  2020cites this paper
• The Potential Use of Blood, Cerebrospinal Fluid, Saliva and Urine as Biological Samples for the Diagnosis of Alzheimer’s Disease

  2020cites this paper
• Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

  2020cites this paper
• The Role of Urine F2-isoprostane Concentration in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Haemorrhage—A Poor Prognostic Factor

  2020cites this paper
• Cerebrospinal fluid oxidative stress markers in Alzheimer's disease

  2020cites this paper
• Okadaic Acid and Hypoxia Induced Dementia Model of Alzheimer’s Type in Rats

  2019cites this paper
• The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers

  2019cites this paper
• AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer’s disease

  2019cites this paper
• Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma

  2019cites this paper
• Biomarkers of Alzheimer's Disease

  2019cites this paper
• Potential protection from Alzheimer’s disease by wheat germ and rice bran nano-form in rat model

  2019cites this paper
• Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation

  2019cites this paper
• Identification d'un profil de marqueurs périphériques lié aux scores cognitifs dans le plasma et les vésicules extracellulaires durant le développement de la maladie d'Alzheimer: évolution de marqueurs liés au stress oxydatif et aux mécanismes physiopathologiques.

  2019cites this paper
• Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome

  2018cites this paper
• Plasma lipid peroxidation biomarkers for early and non‐invasive Alzheimer Disease detection

  2018cites this paper
• The Yin and Yang of carbon nanomaterials in atherosclerosis.

  2018cites this paper
• Edinburgh Explorer Dietary antioxidants and dementia

  2018cites this paper
• Etiology of type 2 diabetes and Alzheimer's disease: Exploring the mitochondria.

  2018cites this paper
• Age-related hearing loss and neurocognitive function: Normal and pathological processes in cognitive ageing

  2018cites this paper
• IRS 2 Insulin receptor substrate-2

  2017cites this paper
• The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics

  2017cites this paper
• The diabetic brain and cognition

  2017cites this paper
• Antioxidants in the Prevention and Treatment of Alzheimer’s Disease

  2017cites this paper
• Edinburgh Explorer Dietary antioxidants and dementia

  2017cites this paper
• The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment

  2017cites this paper
• Peripheral oxidative stress markers in diabetes‐related dementia

  2016cites this paper
• Oxidative challenge in Alzheimer's disease: state of knowledge and future needs

  2016cites this paper
• Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.

  2016cites this paper
• NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION FOLLOWING TRAUMATIC BRAIN INJURY

  2016cites this paper
• Amyloid Plaque-Associated Oxidative Degradation of Uniformly Radiolabeled Arachidonic Acid.

  2016cites this paper
• [Oxidative stress and Alzheimer's disease].

  2016cites this paper
• Increase in CSF F2-isoprostanes is related to cognitive decline in APOE4 carriers

  2015cites this paper
• The isoprostanes--25 years later.

  2015cites this paper
• Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants

  2015cites this paper
• Plasma 8-isoPGF 2 α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

  2015cites this paper
• Today's oxidative stress markers.

  2015cites this paper
• Today's Oxidative Stress Markers Współczesne Markery Stresu Oksydacyjnego

  2015influential citation
• Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update

  2015cites this paper
• Effects of acupuncture at HT7 on glucose metabolism in a rat model of Alzheimer's disease: an 18F-FDG-PET study

  2015cites this paper
• Simulating obstructive sleep apnea patients' oxygenation characteristics into a mouse model of cyclical intermittent hypoxia.

  2015cites this paper
• Isoprostanes - A novel major group of oxidative stress markers.

  2015cites this paper
• Analysing the biological function of PS2V: an aberrant splicing phenomenon or evolutionarily conserved mechanism in Alzheimer’s disease

  2015cites this paper
• Targeting Mitochondria for Healthy Brain Aging

  2015cites this paper
• Correlations between Peripheral Trans Fatty Acids, Lipid PeroxidationMarkers and Cognition in Dementia

  2015cites this paper
• Circulating Oxidative Damage and Antioxidant Defense System Biomarkers in Early Stage Alzheimer’s Disease

  2015cites this paper
• Upregulation of Glycolytic Enzymes, Mitochondrial Dysfunction and Increased Cytotoxicity in Glial Cells Treated with Alzheimer’s Disease Plasma

  2015cites this paper
• Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease.

  2015cites this paper
• Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals.

  2015cites this paper
• Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer's Disease in Carriers of the APOEε4 Allele

  2015cites this paper
• Alzheimer’s Disease and Other Neurodegenerative Disorders

  2015cites this paper
• Smoking and increased Alzheimer's disease risk: A review of potential mechanisms

  2014cites this paper
• Alzheimer’s Disease Pathology and Oxidative Stress: Possible Therapeutic Options

  2014cites this paper
• Oxidative stress and mitochondrial dysfunction in Alzheimer's disease.

  2014cites this paper
• Resveratrol : a polyphenol with multiple health benefits

  2014cites this paper
• Alzheimer’s Disease Pathology and Oxidative Stress: Possible Therapeutic

  2014cites this paper
• Diagnostic methods and biomarkers for Alzheimer’s disease

  2014cites this paper
• Oxidative stress in Alzheimer’s disease

  2014cites this paper
• Neuroinflammation in Alzheimer's, Parkinson's and Huntington's Diseases

  2014cites this paper
• Contrôle de la neuroinflammation par la kinase PKR dans les processus pathologiques de la maladie d'Alzheimer

  2014cites this paper
• Taking clinical judgment out of the equation : a call for the standardization of MCI diagnostic criteria and construction of a model to predict conversion to dementia.

  2014cites this paper
• Oxidative Balance Score, Colorectal Adenoma, and Markers of Oxidative Stress and Inflammation

  2014cites this paper
• Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro

  2014cites this paper
• Oxidative damage in Alzheimer’s disease

  2014cites this paper
• Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting

  2014cites this paper
• The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

  2014cites this paper
• Stress: perspectives on its impact on cognition and pharmacological treatment

  2014cites this paper
• Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus.

  2014cites this paper
• Multiplex biomarkers in blood

  2013cites this paper
• Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ε4 Carriers

  2013cites this paper
• Melatonin protects against amyloid‐β‐induced impairments of hippocampal LTP and spatial learning in rats

  2013cites this paper
• Alzheimer's disease biomarkers: correspondence between human studies and animal models.

  2013influential citation
• OPINION Cerebrospinal fluid biomarkers for pathological processes in Alzheimer’s disease

  2013cites this paper
• Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.

  2013cites this paper
• Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?

  2013cites this paper
• 14 BIOMARKERS OF OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES

  2013cites this paper